Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 28, 2013; 19(32): 5389-5392
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5389
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5389
Intestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis
Sook Hee Chung, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea
Author contributions: Chung SH wrote the manuscript; Park SJ designed the research and performed peer review; Cheon JH analyzed the clinical data and consulted about pathologic data and medical agents; Hong SP, Kim TI and Kim WH reviewed the manuscript.
Correspondence to: Soo Jung Park, MD, PhD, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonseiro, Seodaemun-gu, Seoul 120-752, South Korea. sjpark@yuhs.ac
Telephone: +82-2-22281963 Fax: +82-2-3936884
Received: April 15, 2013
Revised: June 5, 2013
Accepted: July 18, 2013
Published online: August 28, 2013
Revised: June 5, 2013
Accepted: July 18, 2013
Published online: August 28, 2013
Core Tip
Core tip: Here, we report on a patient who was diagnosed with intestinal Behçet’s disease despite treatment with the fully humanized tumor necrosis factor-α blocker (adalimumab) for underlying ankylosing spondylitis. This patient achieved clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen.